Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer

Oncotarget. 2018 Oct 16;9(81):35284. doi: 10.18632/oncotarget.26254.

Naiqing Xu^{1

2

3}, Wenfeng Fang⁴, Libing Mu⁵, Yanna Tang⁴, Lei Gao², Shengxiang Ren⁶, Dengfeng Cao⁷, Lixin Zhou⁸, Aiqun Zhang⁹, Deruo Liu¹⁰, Caicun Zhou⁶, Kwok-Kin Wong¹¹, Lei Yu¹², Li Zhang⁴, Liang Chen^{1

2

3

13}

¹ Graduate School of Peking Union Medical College, Beijing, China.
² National Institute of Biological Sciences, Beijing, China.
³ Chinese Academy of Medical Sciences, Beijing, China.
⁴ Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
⁵ Tsinghua University School of Medicine, Beijing, China.
⁶ Shanghai Pulmonary Hospital, Shanghai, China.
⁷ Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, China.
⁸ Peking University Cancer Hospital, Beijing, China.
⁹ General Hospital of People's Liberation Army, Beijing, China.
¹⁰ Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China.
¹¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
¹² Beijing Tongren Hospital, Capital Medical University, Beijing, China.
¹³ National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, China.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.6461.].